CCL1 and neuroblastoma: The pharmacological rationale for selecting these compounds for further investigation was their minimal neurotoxicity (IC50 > 300 μM) against both human (SH-SY5Y) and murine (Neuro-2a) malignant neuroblastoma cell lines, as well as normal murine fibroblast cells (CCL-1), as demonstrated in our previous study [31].